+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

  • ID: 4775638
  • Report
  • June 2019
  • Region: Global
  • 103 pages
  • IMARC Group
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Abbott
  • Allergan Plc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck
  • Merck & Co. Inc.
  • MORE
The global cephalosporin market size was worth US$ 11.4 Billion in 2018. Cephalosporins are beta-lactam antibiotics that function in the way similar to penicillin. These broad-spectrum drugs help in treating numerous bacterial infections such as pneumonia, kidney infections, bone infections, meningitis and various sexually transmitted diseases (STDs). There are currently five generations of cephalosporin drugs available in the market with a slight difference in their antibacterial spectrum. These medicines are also differentiated on the basis their administration, excretion, absorption and the duration of the effect of cephalosporin on the body. There are two ways to administer cephalosporin drugs, namely, oral and intravenous (IV). A course of oral cephalosporins is generally used for curing minor infections that are easy to treat such as strep throat. Whereas, IVs are utilized for more severe infections, like meningitis, as these medicines reach tissues quickly than those administered orally.

At present, the rapidly increasing water and air pollution are the primary reasons for the prevalence of infectious diseases across the globe. This has provided a boost to the demand for cephalosporin drugs worldwide. Other than this, various organizations around the world are taking initiatives to improve the development and delivery of antibiotic treatments. One such program is the Global Antibiotic Research and Development Partnership (GARDP), which is a not-for-profit R&D organization formed by the Drugs for Neglected Disease initiative (DNDi) and World Health Organization (WHO). It focusses on the promotion of public-private partnerships for increasing R&D of new antimicrobial diagnostics and agents. The formation of these partnerships is expected to play a significant role in the growth of the cephalosporin market. Looking forward, the publisher expects the market to reach a value of US$ 13.3 Billion by 2024, registering a CAGR of around 3% during 2019-2024.

Report Coverage:

Historical, Current and Future Market Trends

Market Breakup by Generation:
First Generation
Second Generation
Third Generation
Fourth Generation
Fifth Generation

Market Breakup by Route of Administration:

Market Breakup by Application:
Respiratory Tract
Skin Infection
Ear Infection
Urinary Tract Infection
Sexually Transmitted Infection

Market Breakup by Region:
Asia Pacific
North America
Middle East and Africa
Latin America

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited (Lupin Pharmaceuticals, Inc., Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott, Ranbaxy, Merck, etc.

Key Questions Answered in This Report:

How has the global cephalosporin market performed so far and how will it perform in the coming years?
What are the key regional markets in the global cephalosporin industry?
What is the breakup of the market based on the generation?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the global cephalosporin industry?
What are the key driving factors and challenges in the global cephalosporin industry?
What is the structure of the global cephalosporin industry and who are the key players?
What is the degree of competition in the global cephalosporin industry?
What are the profit margins in the global cephalosporin industry?
Note: Product cover images may vary from those shown
2 of 4


  • Abbott
  • Allergan Plc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck
  • Merck & Co. Inc.
  • MORE
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Cephalosporin Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Generation
5.4 Market Breakup by Route of Administration
5.5 Market Breakup by Application
5.6 Market Breakup by Region
5.7 Market Forecast

6 Market Breakup by Generation
6.1 First Generation
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Second Generation
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Third Generation
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Fourth Generation
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Fifth Generation
6.5.1 Market Trends
6.5.2 Market Forecast

7 Market Breakup by Route of Administration
7.1 Injection
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Oral
7.2.1 Market Trends
7.2.2 Market Forecast

8 Market Breakup by Application
8.1 Respiratory Tract
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Skin Infection
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Ear Infection
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Urinary Tract Infection
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Sexually Transmitted Infection
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Forecast

9 Market Breakup by Region
9.1 Asia Pacific
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Europe
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 North America
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Middle East and Africa
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Latin America
9.5.1 Market Trends
9.5.2 Market Forecast

10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis
13.1 Price Indicators
13.2 Price Structure
13.3 Margin Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Allergan Plc.
14.3.2 Bristol-Myers Squibb Company
14.3.3 F. Hoffmann-La Roche Ltd.
14.3.4 GlaxoSmithKline plc
14.3.5 Lupin Limited (Lupin Pharmaceuticals, Inc.
14.3.6 Merck & Co. Inc.
14.3.7 Novartis International AG (Sandoz)
14.3.8 Pfizer Inc.
14.3.9 Teva Pharmaceutical Industries Ltd.
14.3.10 Abbott
14.3.11 Ranbaxy
14.3.12 Merck
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Allergan Plc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Lupin Limited (Lupin Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Novartis International AG (Sandoz)
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Abbott
  • Ranbaxy
  • Merck
Note: Product cover images may vary from those shown
5 of 4